LVGO Livongo Health

Livongo Announces Pricing of Public Offering by Selling Stockholders

Livongo Announces Pricing of Public Offering by Selling Stockholders

MOUNTAIN VIEW, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Livongo Health, Inc. (Nasdaq: LVGO) today announced the pricing of its underwritten public offering of 2,777,327 shares of its common stock by certain selling stockholders at a price of $27.00 per share. Such selling stockholders have also granted the underwriters a 30-day option to purchase up to an additional 416,598 shares of common stock at the public offering price, less underwriting discounts and commissions. Livongo will not receive any of the proceeds from the sale of the shares of its common stock being offered by the selling stockholders, and will bear the costs associated with the sale of such shares, other than underwriting discounts and commissions.

This offering is expected to close on or about December 16, 2019, subject to the satisfaction of customary closing conditions.

Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, and J.P. Morgan Securities LLC are acting as lead joint book-running managers for the offering.

The offering is being made only by means of a prospectus relating to the offering. Copies of the prospectus may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526 or by email at  l.gs.com; or J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at  .

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Livongo

Livongo offers a platform to service the whole person and empowers people with chronic conditions to live better and healthier lives, beginning with diabetes and now including hypertension, weight management, diabetes prevention, and behavioral health. Livongo pioneered the category of Applied Health Signals to offer Members clinically-based insights that make it easier to stay healthy. Livongo’s team of data scientists aggregate and interpret substantial amounts of health data and information to create actionable, personalized and timely health signals delivered to Livongo Members exactly when and where they need them. The Livongo approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions.

Investor Contact:

Alex Hughes



650-413-9528

Media Contact:

John Hallock



617-615-7712

 

EN
12/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Livongo Health

 PRESS RELEASE

Livongo Reports Third Quarter 2020 Financial Results

Livongo Reports Third Quarter 2020 Financial Results Third quarter total revenue of $106.1 million, up 126% year-over-yearOver 442,000 enrolled Livongo for Diabetes Members, up 113% year-over-year MOUNTAIN VIEW, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc. (NASDAQ: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced financial results for its third quarter ended September 30, 2020. “Livongo delivered another quarter of greater than 100% revenue growth, driven by stronger than...

 PRESS RELEASE

Livongo to Release Results for the Third Quarter of Fiscal Year 2020

Livongo to Release Results for the Third Quarter of Fiscal Year 2020 MOUNTAIN VIEW, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc., (Nasdaq: LVGO) today announced it will release its financial results for its third quarter of fiscal year 2020 on October 28, 2020, after close of the U.S. stock market. Given the pending transaction with Teladoc Health, Livongo is not hosting a conference call in conjunction with its third quarter of 2020 earnings release. About Livongo Livongo empowers people with chronic conditions to live better and healthier lives, beginning with diabet...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2020 09 08

BHC currently trades well below corporate averages relative to Uniform earnings, with a 9.1x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to fall from 45% in 2019 to 20% in 2024, accompanied by 2% Uniform asset growth going forward. However, analysts have bullish expectations, projecting Uniform ROA to expand to 51% by 2021, accompanied by 3% Uniform asset shrinkage. Furthermore, management is confident about the eye health spinoff, script recovery, and Pro...

 PRESS RELEASE

Livongo to Present at Upcoming Investor Conferences

Livongo to Present at Upcoming Investor Conferences MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc., (Nasdaq: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced that executives from the Company, together with executives from Teladoc Health, will be presenting at the following upcoming investor conferences and discussing their pending merger: Wells Fargo Securities Healthcare Conference on Thursday, September 10 at 8:00 a.m. Eastern TimeMorgan Stanley 18th Annual Glo...

Valens Research
  • Valens Research

LVGO - Embedded Expectations Analysis - 2020 09 02

Livongo Health, Inc. (LVGO:USA) currently trades above historical averages relative to UAFRS-based (Uniform) earnings, with a 166.3x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may be concerned about running at a net loss, Teladoc merger benefits, and the usefulness of their diabetes studies Specifically, management may lack confidence in their ability to generate a net profit, sustain Adjusted EBITDA growth, and continue generating contract wi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch